Polycystic liver disease genes: Practical considerations for genetic testing.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 25 11 2020
revised: 26 01 2021
accepted: 31 01 2021
pubmed: 9 2 2021
medline: 6 7 2021
entrez: 8 2 2021
Statut: ppublish

Résumé

The development of a polycystic liver is a characteristic of the monogenic disorders: autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and autosomal dominant polycystic liver disease (ADPLD). Respectively two and one genes mainly cause ADPKD and ARPKD. In contrast, ADPLD is caused by at least six different genes which combined do not even explain the disease development in over half of the ADPLD population. Genetic testing is mainly performed to confirm the likelihood of developing PKD and if renal therapy is essential. However, pure ADPLD patients are frequently not genetically screened as knowledge about the genotype-phenotype correlation is currently limited. This paper will clarify the essence of genetic testing in ADPLD patients.

Identifiants

pubmed: 33556586
pii: S1769-7212(21)00026-4
doi: 10.1016/j.ejmg.2021.104160
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104160

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Auteurs

Melissa M Boerrigter (MM)

Department of Gastroenterology and Hepatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

Ernie M H F Bongers (EMHF)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Dorien Lugtenberg (D)

Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.

Frederik Nevens (F)

Department of Gastroenterology and Hepatology, University Hospitals KU Leuven, Leuven, Belgium.

Joost P H Drenth (JPH)

Department of Gastroenterology and Hepatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands. Electronic address: joostphdrenth@cs.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH